A-SEEDS is focused on developing innovative cancer therapies, particularly through the advancement of CAR-T cell therapy. This approach involves modifying T lymphocytes, a type of immune cell, to enhance their ability to target and eliminate cancer cells. A-SEEDS employs a unique method known as the piggyback transposon system for gene modification, which allows for the creation of CAR-T cells that maintain their memory function and are less prone to immune exhaustion compared to traditional methods that utilize viral vectors. This technology aims to produce high-quality CAR-T cells that can provide sustained therapeutic effects, thereby improving patient outcomes.

In addition to enhancing the efficacy of CAR-T cells, A-SEEDS is also addressing the challenges associated with solid tumors. The company is developing CAR-T cells capable of targeting multiple cancer antigens simultaneously, which is crucial given the heterogeneous nature of solid tumors. Their proprietary CAR-T cell, designated AP8901, is engineered to recognize and attack cancer cells expressing both EPHB4 and EPHA2 antigens. This multi-targeting strategy is designed to improve the effectiveness of treatment and reduce the likelihood of cancer recurrence, positioning A-SEEDS at the forefront of innovative cancer therapy development.

Japan

A-SEEDS, an innovative biotech company sprouted from Shinshu University, is dedicated to pioneering advanced treatments for life-threatening cancers. Harnessing the potential of non-viral genetic engineering, our cutting-edge immune cell therapy opens up new horizons of hope for patients seeking effective and transformative solutions.

3-1-1, Asahi, #207 Center for Shinshu Medical Innovation of Regional Technology (CSMIT), Matsumoto, Nagano 390-8621, JP

A-SEEDS

Company Details